PharmaLex broadens market access and HEOR reach

The merger with Oblikue Consulting gives PharmaLex deeper pricing and reimbursement expertise and strengthens footprint in Spain

Frankfurt, Germany – 1 June 2021: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has completed the merger with Oblikue Consulting.

One of the leading Spanish health economics and market access consultancies, Oblikue offers support to clients across all stages, from pre- to post-launch, and further assists health authorities in defining healthcare policies to create market access programs for the biotechnology industry.
Oblikue’s clients include many of the largest global pharmaceutical companies, as well as all major Spanish companies.

Through the merger, PharmaLex gains critical scale to its emerging offering in the strategic growth area of pricing and reimbursement (P&R), opening up growth opportunities across the European market. In addition, Oblikue has expertise in LATAM countries with projects in Brazil and Chile.

“Our shared commitment to quality and business pragmatism will benefit customers of both businesses,” commented Max Brosa, founder and general manager of Oblikue Consulting. “Together, we will help customers with all aspects of their market submission – from strategic planning to P&R submission, market access, and beyond.”

“The acquisition of Oblikue fits with our objective to strengthen our health economics and market access expertise and expand our reach in Spain,” noted Dr. Thomas Dobmeyer, CEO PharmaLex. “Oblikue is well-known for its P&R experience, as well as its skill at liaising between pharma customers and healthcare stakeholders and tailoring projects to customer’s needs. We are very pleased to welcome them to PharmaLex,” he added.




About PharmaLex <Confidence beyond compliance>:

PharmaLex is a leading provider of specialised services for the pharma, biotech and medical device industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.

The PharmaLex Group now has over 1400 employees, with 41 offices in 22 countries and more than 600 satisfied clients worldwide.

 For further information, please contact:

Ms. Eva Keck
PharmaLex GmbH; Director, Business Development Operations
+49 621 18 15 38 0
Harrlachweg 6
68163 Mannheim
Germany Contact Us

Scroll to Top